Home monitoring of patients with cystic fibrosis to identify and treat acute pulmonary exacerbations eICE study results

American Journal of Respiratory and Critical Care Medicine

Volumn 196, Issue 9, 2017, Pages 1144-1151

  Lechtzin, Noah ^a   Mayer Hamblett, Nicole ^b,c   West, Natalie E ^a   Allgood, Sarah ^a   Wilhelm, Ellen ^b   Khan, Umer ^c   Aitken, Moira L ^b   Ramsey, Bonnie W ^b,c   Boyle, Michael P ^a,d   Mogayzel, Peter J ^a   Gibson, Ronald L ^b,c   Orenstein, David ^e   Milla, Carlos ^f   Clancy, John P ^g   Antony, Veena ^h   Goss, Christopher H ^b,c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d CYSTIC FIBROSIS FOUNDATION   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF CINCINNATI   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Clinical trial; Cystic fibrosis; Home monitoring; Pulmonary exacerbation

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE EXACERBATION; EARLY DIAGNOSIS; EARLY INTERVENTION; FEMALE; FORCED EXPIRATORY VOLUME; HOME MONITORING; HUMAN; LUNG DISEASE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; WEIGHT CHANGE; CLINICAL TRIAL; LUNG; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; SELF CARE;

ADULT; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LUNG; MALE; SELF CARE; SPIROMETRY;

EID: 85032708784     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201610-2172OC     Document Type: Article

References (32)

1. Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd C, Elbert A, Petren KM, Marshall BC. The Cystic Fibrosis Foundation patient registry: design and methods of a national observational disease registry. Ann Am Thorac Soc 2016;13:1173-1179.
2. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation patient registry: 2013 annual report. Bethesda, MD: Cystic Fibrosis Foundation; 2014.
3. MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH, Marshall BC. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med 2014;161:233-241.
4. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352.
5. Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med 2005;171:1053-1059.
6. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002;34:91-100.
7. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, Wilmott RW. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72.
8. Dobbin CJ, Bartlett D, Melehan K, Grunstein RR, Bye PT. The effect of infective exacerbations on sleep and neurobehavioral function in cystic fibrosis. Am J Respir Crit Care Med 2005;172:99-104.
9. Sanders DB, Bittner RC, Rosenfeld M, Hoffman LR, Redding GJ, Goss CH. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182: 627-632.
10. Parkins MD, Rendall JC, Elborn JS. Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest 2012;141:485-493.
11. Schechter MS, Leonard A, Nash J, Quinton HB, Richards K, Sabadosa K, Vanden Branden S. Benchmarking: signature themes. Pediatr Pulmonol 2006;41:122-123.
12. Johnson C, Butler SM, Konstan MW, Morgan W, Wohl ME. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003;123:20-27.
13. International Diabetes Federation Guideline Development Group. Global guideline for type 2 diabetes. Diabetes Res Clin Pract 2014; 104:1-52.
14. Stewart S, Marley JE, Horowitz JD. Effects of a multidisciplinary, home-based intervention on unplanned readmissions and survival among patients with chronic congestive heart failure: a randomised controlled study. Lancet 1999;354:1077-1083.
15. Goss CH, Edwards TC, Ramsey BW, Aitken ML, Patrick DL. Patient-reported respiratory symptoms in cystic fibrosis. J Cyst Fibros 2009; 8:245-252.
16. Lechtzin N, West N, Allgood S, Wilhelm E, Khan U, Mayer-Hamblett N, Aitken ML, Ramsey BW, Boyle MP, Mogayzel PJ Jr, et al. Rationale and design of a randomized trial of home electronic symptom and lung function monitoring to detect cystic fibrosis pulmonary exacerbations: the early intervention in cystic fibrosis exacerbation (eICE) trial. Contemp Clin Trials 2013;36:460-469.
17. Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther 1974;15: 443-453.
18. American Thoracic Society. Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 1995;152:1107-1136.
19. Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG Jr. Pulmonary function between 6 and 18 years of age. Pediatr Pulmonol 1993;15: 75-88.
20. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999;159:179-187.
21. Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of the Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest 2005;128:2347-2354.
22. Robson KS, West AJ. Improving survival outcomes in lung transplant recipients through early detection of bronchiolitis obliterans: daily home spirometry versus standard pulmonary function testing. Can J Respir Ther 2014;50:17-22.
23. Finkelstein SM, Wielinski CL, Kujawa SJ, Loewenson R, Warwick WJ. The impact of home monitoring and daily diary recording on patient status in cystic fibrosis. Pediatr Pulmonol 1992;12:3-10.
24. Murgia F, Bianciardi F, Solvoll T, Tagliente I, Bella F, Carestia A, Bella S. Telemedicine home program in patients with cystic fibrosis: results after 10 years. Clin Ter 2015;166:e384-e388.
25. Roehrer E, Cummings E, Beggs S, Turner P, Hauser J, Micallef N, Ellis L, Reid D. Pilot evaluation of web enabled symptom monitoring in cystic fibrosis. Inform Health Soc Care 2013;38:354-365.
26. Roehrer E, Cummings E, Turner P, Hauser J, Cameron-Tucker H, Beggs SA, Micallef NA, Wainwright C, Cheney J, Jessup M, et al. Supporting cystic fibrosis with ICT. Stud Health Technol Inform 2013;183:137-141.
27. Cummings E, Hauser J, Cameron-Tucker H, Fitzpatrick P, Jessup M, Walters EH, Reid D, Turner P. Enhancing self-efficacy for self-management in people with cystic fibrosis. Stud Health Technol Inform 2011;169:33-37.
28. Quittner AL, Zhang J, Marynchenko M, Chopra PA, Signorovitch J, Yushkina Y, Riekert KA. Pulmonary medication adherence and health-care use in cystic fibrosis. Chest 2014;146:142-151.
29. Goss CH. Early intervention in pulmonary exacerbation [abstract]. Pediatr Pulmonol 2011;46:A331.
30. Flume PA, Mogayzel PJ, Robinson KA, Goss CH, Rosenblatt RL, Kuhn RJ, Marshall BC. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am J Respir Crit Care Med 2009;180: 802-808.
31. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, Coquillette S, Fieberg AY, Accurso FJ, Campbell PW III. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-1756.
32. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-240.